Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2017 · 10-Q
Revenue$11.36M$11.36M+26.4% vs Q3 2016 Net Income-$77.14M-$77.14MN/M vs Q3 2016 EPS Diluted-$1.59-$1.59N/M vs Q3 2016 Operating Income-$79,017,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$79,734,000N/M Margins · derivedOperating margin-695.7%+11.2 pt vs Q3 2016
Net margin-679.1%+20.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 1, 2017 · 32 d after period end